Madrigal Reports Strong Rezdiffra Sales Nearing $1 Billion and Expands MASH Pipeline with Multiple New Programs
MDGL sits 70% above its 52-week low of $265.
Summary
Madrigal Pharmaceuticals reported nearly $1 billion in Rezdiffra sales for its first full year and significantly expanded its MASH pipeline with new licensing agreements, reinforcing its market leadership and future growth strategy.
Key Events · Earnings and Guidance · MDGL
-
Strong Rezdiffra Sales Performance
Reported fourth-quarter net sales of $321.1 million and full-year 2025 net sales of $958.4 million for Rezdiffra, its MASH treatment, in its first full year of launch.
-
Significant Pipeline Expansion
Licensed global rights to six preclinical siRNA programs and an exclusive global license for ervogastat, a Phase 2 oral DGAT-2 inhibitor, alongside an oral GLP-1 (MGL-2086), diversifying its MASH therapeutic portfolio.
-
Positive Clinical Data for F4c MASH
Presented two-year data from the NAFLD-1 trial's F4c cohort, showing Rezdiffra significantly improved liver stiffness, fibrosis biomarkers, and markers of clinically significant portal hypertension risk in patients with compensated MASH cirrhosis.
-
Solid Financial Position
Ended 2025 with $988.6 million in cash, cash equivalents, restricted cash, and marketable securities, supported by a $500 million senior secured credit facility secured in July 2025.
Analysis · MDGL · Life Sciences
Madrigal Pharmaceuticals delivered a highly positive earnings report, showcasing robust commercial success for Rezdiffra, its flagship MASH treatment, with nearly $1 billion in sales during its first full year on the market. This strong performance is complemented by an aggressive and strategic expansion of its MASH pipeline, including licensing multiple preclinical siRNA programs, a Phase 2 DGAT-2 inhibitor (ervogastat), and an oral GLP-1 agonist. These moves signal a significant shift towards developing combination therapies and diversifying the company's future growth drivers beyond a single product. The positive two-year clinical data for Rezdiffra in compensated MASH cirrhosis (F4c) further strengthens its market position and potential. The company's solid cash position and recent credit facility provide ample resources for continued R&D and commercialization efforts. This filing indicates strong execution on both commercial and strategic fronts, positioning Madrigal as a leader in the MASH therapeutic space.
At the time of this filing, MDGL was trading at $451.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.2B. The 52-week trading range was $265.00 to $615.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.